TABLE 3.
Recurrence and survival
| All patientsa (N = 122/126) | SLNB performed (N = 62) | Positive SLNB (N = 18) | Negative SLNB (N = 44) | Presented as stage IV (N = 40) | |
|---|---|---|---|---|---|
| Total recurrences, n (%) | 27 (22.1) | 13 (21) | 8 (44.4) | 5 (11.4) | NA |
| First site of recurrence, n (%) | |||||
| Local | 3 (2.5) | 2 (3.2) | 1 (5.6) | 1 (2.3) | |
| Regional | 14 (11.5) | 4 (6.5) | 3 (16.7) | 1 (2.3) | |
| Distant | 8 (6.6) | 5 (8.1) | 3 (16.7) | 2 (4.5) | |
| Unknown | 2 (1.6) | 2 (3.2) | 1 (5.6) | 1 (2.3) | |
| Alive, n (%) | 106 (84.1) | 53 (85.5) | 13 (72.2) | 40 (90.9) | 1 (25) |
| Died of disease, n (%) | 19 (15.1) | 9 (14.5) | 5 (27.8) | 4 (9.1) | 3 (75) |
| Died of other causes, n (%) | 1 (0.8) | 0 | 0 | 0 | 0 |
SLNB sentinel lymph node biopsy, NA not applicable
a
In evaluating recurrences, the 4 patients who presented with stage IV disease were excluded, leaving 122 patients. For the purposes of analyzing survival, the 4 patients who presented with stage IV disease were included, giving a total of 126 patients evaluated